Mode
Text Size
Log in / Sign up
N/A N=34 Treatment

Blood Lactate Concentrations With and Without Exercise in Parkinson's Disease and Multiple Sclerosis Patients

Parkinson's Disease · Multiple Sclerosis

Enrolled (actual)
34
Serious AEs
0.0%
Results posted
Nov 2015
Primary outcome: Primary: Blood Lactate Response — 1.7; 1.6; 1.2; 2.3 mmol/L

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands) (Device)
Age
Adult, Older Adult · 45+ yrs
Sex
All
Sponsor
Florida State University
Primary completion
Nov 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Blood Lactate Response
1.7; 1.6; 1.2; 2.3; 2.8; 2.5
SECONDARY
Resting Energy Expenditure
1338; 1262; 1521

Summary

Fatigue is one of the most common and debilitating symptoms experienced in Parkinson's Disease (PD) and Multiple Sclerosis (MS). There are multiple proposed mechanisms of disorder-related fatigue, however, it is unknown whether PD or MS patients experience compromised blood lactate responses to an acute bout of exercise, subjecting them to exercise-related fatigue. These populations may experience higher energy expenditure at rest due to increased rigidity, however, limited data exists investigating resting energy expenditure in these populations. Researchers hypothesize that PD and MS patients will display higher resting energy expenditure than healthy age-matched controls, and that level of energy expenditure will correlate with amount of rigidity or spasticity. Also, we hypothesize that baseline levels of lactate will not be different between PD/MS and control groups, but post-exercise blood lactate levels will be significantly higher in the PD/MS groups.

Eligibility Criteria

Inclusion Criteria

  • Parkinson's Disease Stage I-IV (be standard criteria H&Y scale)
  • Multiple Sclerosis
  • Healthy, age-matched controls
  • 45 to 90 years old

Exclusion Criteria

  • Dementia
  • Co-morbid neurologic factors
  • Individuals without independent ambulation
  • Significant heart and respiratory disease
  • Debilitating arthritis
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02184494). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search